Research
Neural
The unique combination of naltrexone and bupropion in NB-ER may work together to target POMC cells to prevent endogenous negative feedback, thereby decreasing appetite.
Understanding the mechanism can help practitioners explain the treatment's effects to patients.
StrongSupportsmedium confidence
The unique combination of naltrexone, an opioid receptor antagonist, and bupropion, a norepinephrine-dopamine reuptake inhibitor...may work together to target POMC cells to prevent endogenous negative feedback, thereby decreasing appetite.
Why this rating
Based on the clinical review's discussion of mechanisms.
Source
Appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion as treatment for obesity in primary care
Ethan Lazarus · Obesity Pillars · 2025
reviewCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →